About Syneos Health, Inc
Syneos Health, Inc. provides biopharmaceutical outsourcing solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers various services spanning Phases I to IV of clinical development, including full service global studies, as well as individual service offerings, such as clinical monitoring, investigator recruitment, patient recruitment, data management, and study startup to assist customers with their drug development process. The Commercial Solutions segment provides commercialization services comprising deployment solutions; communications solutions, such as public relations, advertising, and medical communications; and consulting services. Its customers include small, mid-sized, and large companies in the pharmaceutical, biotechnology, and medical device industries. Syneos Health, Inc. has a partnership with VBI Vaccines Inc. for the commercialization of 3-antigen prophylactic hepatitis B vaccine in the United States, Europe, and Canada, which is in pending regulatory approvals. The company was formerly known as INC Research Holdings, Inc. and changed its name to Syneos Health, Inc. in January 2018. Syneos Health, Inc. was incorporated in 2010 and is headquartered in Morrisville, North Carolina Address: 1030 Sync Street, Morrisville, NC, United States, 27560-5468
Syneos Health, Inc News and around…
Latest news about Syneos Health, Inc (SYNH) common stock and company :
Investors about optimistic about Syneos Health (SYNH) given its better-than-expected results as well as strong segmental performance during the third quarter.
Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Syneos Health, Inc...
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
In the latest look at stocks ordered by largest market capitalization, Russell 3000 component Syneos Health Inc (SYNH) was identified as having a larger market cap than the smaller end of the S&P 500, for example Newell Brands Inc (NWL), according to The Online Investor. Click here to find out the top S&P 500 components ordered by average analyst rating » Market capitalization is an important data point for investors to keep an eye on, for various reasons..
(Bloomberg) -- Laboratory Corp. of America Holdings is in talks to combine some of its assets with Syneos Health Inc., according to people with knowledge of the matter. Most Read from BloombergWhy Hong Kong Is Building Apartments the Size of Parking SpacesAmazon Sued Over Crashes by Drivers Rushing to Make DeliveriesHong Kong's New Museum Tries to Please Art World — and BeijingFarmers Take on ‘Post-Apocalyptic’ Food CrisisThe companies are discussing a deal in which part of Labcorp’s Covance cli
Laboratory Corp of America Holdings(NYSE: LH) is in talks to combine some of its assets withSyneos Health ...
MORRISVILLE, N.C., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced that the Company is scheduled to present at two upcoming investor conferences: Chief Executive Officer Alistair Macdonald is scheduled to present at the Jefferies London Healthcare Conference on November 18, 202, at 8:00 a.m. GMTChief Financial Officer Jason Meggs is scheduled to present at the Evercore ISI 4th Annual HealthCONx Co
By John Vandermosten, CFA NASDAQ:NOVN READ THE FULL NOVN RESEARCH REPORT Third Quarter 2021 Results On November 10, 2021, Novan Inc. (NASDAQ:NOVN) reported third quarter financial results in a press release concurrent with the filing of Form 10-Q . A conference call and webcast was also held to update investors on financial and operational results. Most recently, the FDA conditionally accepted
Upgrades For IGM Biosciences Inc (NASDAQ:IGMS), Wedbush upgraded the previous rating of Neutral to Outperform. IGM ...
Syneos Health (SYNH) reports better-than-expected results for third-quarter 2021 on strength in Clinical Solutions and Commercial Solutions arms driving the top line.
Syneos Health shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 79 to 83.
SYNH earnings call for the period ending September 30, 2021.
According to Benzinga Pro, during Q3, Syneos Health (NASDAQ:SYNH) earned $113.36 million, a 35.46% increase from the preceding quarter. ...
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Horizon Announces Retirement ...
Syneos Health (SYNH) delivered earnings and revenue surprises of 3.39% and 0.18%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Highlights Third quarter revenue of $1,348.2 million increased 22.7% year-over-year.Clinical Solutions net new business awards of $1,353.8 million for the third quarter, representing year-over-year growth of 35.0% and a book-to-bill ratio of 1.30x, and $5,322.2 million for the trailing twelve months, representing year-over-year growth of 12.3% and a book-to-bill ratio of 1.39x.Commercial Solutions net new business awards of $276.9 million for the third quarter, representing year-over-year growth
Companies Reporting Before The Bell • R.R.Donnelley & Sons (NYSE:RRD) is likely to report quarterly earnings at ...
Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Riot Blockchain Inc (RIOT), where a total volume of 161,563 contracts has been traded thus far today, a contract volume which is representative of approximately 16.2 million underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 116.5% of RIOT's average daily trading volume over the past month, of 13.9 million shares..
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly ...
Syneos Health (SYNH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
A Relative Strength Rating upgrade for Syneos Health shows improving technical performance. Will it continue?
Syneos Health shows rising price performance, earning an upgrade to its IBD Relative Strength Rating
Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Syneos Health Inc (SYNH), where a total volume of 2,705 contracts has been traded thus far today, a contract volume which is representative of approximately 270,500 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 54.3% of SYNH's average daily trading volume over the past month, of 497,795 shares..
It's only natural that many investors, especially those who are new to the game, prefer to buy shares in 'sexy' stocks...
MORRISVILLE, N.C., Oct. 19, 2021 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, will release its third quarter 2021 financial results on Wednesday, November 3rd, 2021, prior to its earnings call at 8:00 a.m. ET. Participants may access the conference call live via webcast on the Investor Relations section of the Syneos Health website at investor.syneoshealth.com. To participate via telephone, please register in advance at thi
We at Insider Monkey have gone over 873 13F filings that hedge funds and prominent investors are required to file by the SEC. The 13F filings show the funds’ and investors’ portfolio positions as of June 30th. In this article, we look at what those funds think of Syneos Health, Inc. (NASDAQ:SYNH) based on that […]
Syneos Health's (SYNH) recent acquisition boosts the company's ability to deliver strategic insights and technology-enabled solutions that address the customers' most complex data challenges.
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Revance Clarifies Gabellar ...
Morrisville-based Syneos Health has acquired a health care-focused data science firm with the aim to accelerate performance across the company's operations.
Acquisition Delivers AI and Data Engineering Expertise, Enterprise Analytics and Technology-Enabled Solutions to Accelerate Customer PerformanceMORRISVILLE, N.C., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced the acquisition of RxDataScience, a leading healthcare-focused data analytics, data management and artificial intelligence (AI) company. Together, Syneos Health and RxDataScience will offer